ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Hypomethylation of GNA15 Promotes Pancreatic Ductal Adenocarcinoma Progression and Macrophage M2 Polarization via STAT3-CXCL8 Axis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The complexity of pancreatic ductal adenocarcinoma (PDAC) progression, coupled with the lack of effective immunotherapy, underscores the imperative to deepen our understanding of its mechanisms and identify suitable immune-targeted interventions. The G protein alpha subunit 15 (GNA15) is significantly upregulated in PDAC and correlates with poor prognosis in patients with PDAC. Mechanistically, our study demonstrates that TET3 upregulates GNA15 expression through demethylation in PCs, and the highly expressed GNA15 activates the phosphorylation of STAT3 via the GP130-JAK signaling pathway, thereby promoting the expression and release of CXCL8. Subsequently, CXCL8 released by PCs binds to CXCR1 or CXCR2 in macrophages to promote M2 polarization. Additionally, high GNA15 expression was associated with Gemcitabine resistance, and the combination of Reparixin and Gemcitabine has shown favorable antitumor efficacy in PDAC. Collectively, we elucidated that GNA15 drives PDAC progression and M2 macrophage polarization via the STAT3-CXCL8 axis and established targeting GNA15-STAT3-CXCL8 as a novel strategy to improve PDAC therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.